The administration of bexarotene has been shown to enhance clearance of soluble Aβ from the brain within hours in an ApoE-dependent manner in a mouse model of AD, providing a rationale to develop this anticancer drug as a potential AD therapeutic agent [75]. Here, APOE is linked to Alzheimer disease.